SG185592A1 - Improved process for a folate-targeted agent - Google Patents

Improved process for a folate-targeted agent Download PDF

Info

Publication number
SG185592A1
SG185592A1 SG2012084190A SG2012084190A SG185592A1 SG 185592 A1 SG185592 A1 SG 185592A1 SG 2012084190 A SG2012084190 A SG 2012084190A SG 2012084190 A SG2012084190 A SG 2012084190A SG 185592 A1 SG185592 A1 SG 185592A1
Authority
SG
Singapore
Prior art keywords
formula
compound
buffer
treating
reaction mixture
Prior art date
Application number
SG2012084190A
Other languages
English (en)
Inventor
Daniel S Reno
Katheryn Marie Stanford
Iontcho Radoslavov Vlahov
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of SG185592A1 publication Critical patent/SG185592A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG2012084190A 2010-05-19 2011-05-19 Improved process for a folate-targeted agent SG185592A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34644410P 2010-05-19 2010-05-19
US35102210P 2010-06-03 2010-06-03
PCT/US2011/037134 WO2011146707A1 (en) 2010-05-19 2011-05-19 Improved process for a folate-targeted agent

Publications (1)

Publication Number Publication Date
SG185592A1 true SG185592A1 (en) 2012-12-28

Family

ID=44992057

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012084190A SG185592A1 (en) 2010-05-19 2011-05-19 Improved process for a folate-targeted agent

Country Status (11)

Country Link
US (2) US20130065841A1 (https=)
JP (1) JP2013526577A (https=)
KR (1) KR20130079431A (https=)
CN (1) CN102984943B (https=)
BR (1) BR112012029458A2 (https=)
CA (1) CA2799391A1 (https=)
IL (1) IL222964A0 (https=)
MX (1) MX2012013250A (https=)
RU (1) RU2012154914A (https=)
SG (1) SG185592A1 (https=)
WO (1) WO2011146707A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6676650B2 (ja) 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
US20200323991A1 (en) * 2016-03-29 2020-10-15 Endocyte, Inc. Pbd conjugates for treating diseases
WO2019196999A1 (en) 2018-04-11 2019-10-17 Radisurf Aps Compositions for forming polymer brushes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381177C (zh) * 2003-01-27 2008-04-16 恩多塞特公司 维生素受体结合递药缀合物
CN100423778C (zh) * 2003-11-25 2008-10-08 上海复旦张江生物医药股份有限公司 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives

Also Published As

Publication number Publication date
CN102984943B (zh) 2016-01-13
CA2799391A1 (en) 2011-12-04
US20130065841A1 (en) 2013-03-14
WO2011146707A1 (en) 2011-11-24
KR20130079431A (ko) 2013-07-10
IL222964A0 (en) 2013-02-03
MX2012013250A (es) 2013-03-05
JP2013526577A (ja) 2013-06-24
US20140066593A1 (en) 2014-03-06
CN102984943A (zh) 2013-03-20
RU2012154914A (ru) 2014-06-27
BR112012029458A2 (pt) 2015-10-20

Similar Documents

Publication Publication Date Title
AU2020214507B2 (en) Bi-ligand drug conjugate and use thereof
EP3152223B1 (en) Mitomycin conjugate
US20070020620A1 (en) Compositions and methods for coupling a plurality of compounds to a scaffold
JP2010503706A (ja) リジン系ポリマーリンカー
JP2010536986A (ja) ピリジルジスルフィド部分を含有するポリマーリンカー
WO2015022504A2 (en) Peptide conjugates
AU2020204250A1 (en) One-pot process for preparing intermediate of antibody-drug conjugate
CN109939242A (zh) 抗体前药偶联物及其制备和应用
Gonçalves et al. Design, Synthesis, and Evaluation of Original Carriers for Targeting Vascular Endothelial Growth Factor Receptor Interactions: Gonçalves et al.
SG185592A1 (en) Improved process for a folate-targeted agent
EP3684785B1 (en) N-methylated cyclic peptides and their prodrugs
Tripodi et al. Development of novel cyclic NGR peptide–daunomycin conjugates with dual targeting property
EP4417618A1 (en) Epha2 bicyclic peptide ligand and conjugate thereof
Kubi et al. Cell-penetrating and mitochondrion-targeting molecules
WO2000073326A2 (en) Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use
EP3950700A1 (en) Peptide complex and production method therefor, and use of said peptide complex
EP4201429A1 (en) Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor
CN111205350A (zh) 作为组蛋白脱乙酰酶抑制剂的大环硫代酸酯前体药物
EP2571362A1 (en) Improved process for a folate-targeted agent
CN110551179B (zh) 一种经修饰的抗hiv多肽及其制备方法和用途
Ding et al. Design and synthesis of multivalent drug delivery system with CA IX inhibitors as ligands
WO2006067173A2 (en) Antithrombotic dual inhibitors comprising a biotin residue
EP3556767A1 (en) Cell penetrating peptides
EP4365184A1 (en) Analysis method for peptide bound to carrier for liquid phase peptide synthesis
Dissanayake Studies towards the synthesis of DNA methyltransferase inhibitors and peptide drug conjugate systems for autosomal polycystic kidney disease